Teplizumab curbs beta-cell death in new-onset type 1 diabetes

02/26/2013 | PhysiciansBriefing.com

Patients with new-onset type 1 diabetes had higher rates of beta-cell death compared with those who had long-standing diabetes and those without diabetes, a study found. However, teplizumab treatment was associated with lower beta-cell death and better beta-cell function in patients with new-onset diabetes, researchers wrote in the journal Diabetes.

View Full Article in:

PhysiciansBriefing.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Executive Officer
UCare Minnesota
Minneapolis, MN